study, necropsies were performed on 604 adult blacks from southern Africa and one of five grades of hepatic and splenic iron was assigned based on the Prussian blue reaction obtained when a piece of tissue was dipped in a mixture of potassium ferrocyanide and hydrochloric acid. Using logistic regression models, we found that iron overload was strongly associated with the findings of cirrhosis in HCC. The frequency of cirrhosis was 11% and tuberculosis (p<0.001). Secondly, we reviewed all 320 diagnostic liver biopsy specimens processed at the University of Zimbabwe from 1992 to 1994. HCC was present in 19% of the evaluable specimens, cirrhosis in 21%, and high grades of iron in 19%. We found significant associations between the presence of iron overload and the histological diagnoses of cirrhosis and HCC.

We do not completely share the pessimism of Drs Walker and Segal with regard to changing the method of preparation of traditional beer and to instituting a phlebotomy programme. The iron drums that are now used to prepare beer have replaced clay pots around the turn of the century, but these clay utensils are still used in most rural communities to prepare food and other forms of beverages. It seems feasible to us to encourage the use of a rural based method of preparing traditional beer in place of the newer and more convenient, but probably more dangerous, iron drums. For the past two years our research team has been conducting a rural based study of dietary iron overload. We have been struck by the overwhelming level of cooperation that we have been able to obtain through close and regular contact with the rural communities. Despite the need for venesection and high awareness of the problem of HIV, it has been unusual for subjects to refuse to take part.

In summary, we believe the available data point to both HCC and dietary iron overload as major health problems in rural Africa. There is a strong body of evidence to suggest an association between the two conditions. Major initiatives are needed to combat these diseases beginning in the communities where the people live.

DONNIE TCHAOA GANKGANDO
Department of Medicine and the Clinical Epidemiological Unit, University of Zimbabwe School of Medicine, PO Box A178, Avondale, Harare, Zimbabwe

VICTOR ROLAND GORDEUR
Department of Medicine, George Washington University Medical Center, Washington, USA

Analysis of biological variables in Crohn's disease

EDITOR,—We wish to comment on the paper by Sahmoud et al (1995; 37: 811–8) where the authors suggested the following features: age, interval since previous relapse, and colonic involvement as powerful prognostic factors to predict relapse in quiescent Crohn's disease. We also followed up for 18 months 107 patients with Crohn's disease (request1 and we used laboratory tests enhanced by clinical characteristics for predicting relapse.

Interestingly, our results about clinical characteristics were, for some aspects, similar to those obtained in a large group. A Cox regression analysis indicated interval since previous relapse, previous surgery, location (ileum versus non-ileum), and occurrence of post-surgical clinical characteristics to be predictors of relapse; however an intercorrelation was found among these characteristics and particularly between previous surgery and location (but simultaneous Cox regression indicated that surgery would be more powerful than location). Thus two groups of risk of relapse according to clinical characteristics were defined: (a) favourable group consisted of patients in clinical remission after last relapse for at least 48 months or patients with less than 24 months but who had undergone surgery without subsequent post surgical clinical recurrence; (b) unfavourable group consisted of patients in clinical remission for less than 24 months not included in the favourable group.

In the French study surgery was not identified as a prognostic factor; this could be explained because in that study quiescent disease induced by surgery seems to be excluded and ileal location (this reason as previous resection) is present in a small number of patients in comparison with colonic location. In our experience duration of illness was not a useful predictor of relapse; we did not study age of durations.

In the study by Sahmoud et al biological indicators such as albumin and erythrocyte sedimentation rate did not result in predicting the course of the disease; in contrast, in our experience, laboratory tests seem to be extremely useful for this aim. In a previous study a prognostic index based on laboratory tests was proposed. In our last study1 the ability of this index to predict relapse was validated and a simplified application was proposed; patients with at least one of the laboratory tests changed (α1 acid glycoprotein >130 mg/dl, or α2 globulin >9-0 g/ml or erythrocyte sedimentation rate >40 mm/h, or all three) presented within 18 months a relapse rate of 75% whereas in patients with normal tests it was 13%. In our study nine among 18 false-negative (normal laboratory tests with subsequent relapses) were presented by patients with previous remission <3 months who had recently stopped corticosteroid treatment. Usually, however, values of laboratory tests are rapidly normalised by a period of corticosteroid treatment and it is shown14 that these tests, performed during or immediately after corticosteroids have poor ability in discriminating the clinical outcome. In our opinion the use of biological indicators could show a prognostic ability of sedentation rate and albumin because at least 64 patients among 167 included were treated with corticosteroids at the entry of the study (placebo group of the trial about differentof prednisolone treatment in patients in clinical remission after prednisolone treatment for an acute attack).

We agree, however, with Sahmoud's conclusion about the necessity of identifying patients with different risks of relapse in quiescent Crohn's disease. In our study, at the end of 18 months of follow up, the predicted proportion of patients with relapse was 13% and 31% in the subgroup with normal laboratory tests and favourable and unfavourable clinical characteristics respectively, and 87% in patients with abnormal tests and unfavourable characteristics. Thus risk of relapse varies substantially among different subgroups of patients with clinical remission; prediction of this risk is helpful not only for a correct design of clinical trials, but also, in clinical practice, for timing subsequent clinical visits and for selecting of groups of patients where preventive treatment could be justified.

C BRIGNOLA
C BELLOLI
G DE SIMONE
P BANNO
G NICETTI
A BELLUZZI
Istituto di Clinica Medica e Gastroenterologia, Policlinico S, Orsola, V, Maastricht 9, 40128 Bologna, Italy

Reply

EDITOR,—Thank you for referring the interesting comments of Brignola et al to us concerning our article. The Italian group has considerable experience in investigating the value of biological parameters in Crohn's disease and has published several research results in that field. One of the most recent publications1 suggests a prognostic index for predicting relapse in quiescent Crohn's disease patients using the baseline blood values of α1 glycoprotein, α2 globulin, β globulin, and albumin. The index was based on data from 41 patients who had been in remission for at least six months. The same study suggested that the blood values of C-reactive protein and α1 antitrypsin were of no predictive value and the predictive value of some other biological variables were much less important, namely the haemoglobin concentration, the white blood cell count, serum iron, albumin, and γ globulin blood values.

Analysis of biological variables in Crohn's disease.

C Brignola, C Belloli, G De Simone, M Campieri, P Gionchetti and A Belluzzi

*Gut* 1996 38: 938-939
doi: 10.1136/gut.38.6.938

Updated information and services can be found at:
http://gut.bmj.com/content/38/6/938.1.citation

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/